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Abstract
Backgrounds: Two SNPs in melatonin receptor 1B gene, rs10830963 and rs1387153 showed significant associations
with fasting plasma glucose levels and the risk of Type 2 Diabetes Mellitus (T2DM) in previous studies. Since T2DM
and gestational diabetes mellitus (GDM) share similar characteristics, we suspected that the two genetic
polymorphisms in MTNR1B may be associated with GDM, and conducted association studies between the
polymorphisms and the disease. Furthermore, we also examined genetic effects of the two polymorphisms with
various diabetes-related phenotypes.
Methods: A total of 1,918 subjects (928 GDM patients and 990 controls) were used for the study. Two MTNR1B
polymorphisms were genotyped using TaqMan assay. The allele distributions of SNPs were evaluated by x
2 models
calculating odds ratios (ORs), 95% confidence intervals (CIs), and corresponding P values. Multiple regressions were
used for association analyses of GDM-related traits. Finally, conditional analyses were also performed.
Results: We found significant associations between the two genetic variants and GDM, rs10830963, with a
corrected P value of 0.0001, and rs1387153, with the corrected P value of 0.0008. In addition, we also found that
the two SNPs were associated with various phenotypes such as homeostasis model assessment of beta-cell
function and fasting glucose levels. Further conditional analyses results suggested that rs10830963 might be more
likely functional in case/control analysis, although not clear in GDM-related phenotype analyses.
Conclusion: There have been studies that found associations between genetic variants of other genes and GDM,
this is the first study that found significant associations between SNPs of MTNR1B and GDM. The genetic effects of
two SNPs identified in this study would be helpful in understanding the insight of GDM and other diabetes-related
disorders.
Background
The prevalence of type 2 diabetes mellitus (T2DM) in
Korean population has dramatically increased over last
decades. Although Asian populations traditionally had a
low percentage of T2DM patients, it has increased drasti-
cally in recent decades. This is largely due to the fact that
Asian countries are adopting western lifestyle and diets.
However, a recent discovery of diabetes-susceptible loci
on human chromosomes suggest that genetic factors may
also play a role in the disease development [1].
Gestational diabetes mellitus (GDM) is a condition in
which pregnant women exhibit glucose intolerance in
various degrees [2], affecting approximately 2-14% of
pregnancies [1,3,4]. Women with GDM show similar
physiological and genetic characteristics found in dia-
betes outside of pregnancy, and not surprisingly, women
with GDM possess higher risk for developing T2DM
when they are not pregnant. Therefore, studying GDM is
a good way to study early pathogenesis of diabetes and
possibly develop treatment or remedy for the disease [5].
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[6,7], there are relatively fewer genetic studies for GDM.
Advance of technology in the genetics field has pro-
vided us with a number of useful tools to study human
genome. Among them, genome wide association studies
(GWAS) are a powerful and useful way to detect genes
associated with various diseases, including diabetes.
Recently, a couple of studies have revealed that the
genetic variants in melatonin receptor 1 B (MTNR1B)
gene are associated with T2DM and fasting glucose
levels [8,9]. MTNR1B gene encodes MT2 protein which,
along with MT1 protein encoded by MTNR1A, is one of
two high-affinity forms of melatonin receptor. This gene
product is also an integral membrane protein forming a
G-protein coupled 7-transmembrane receptor. Melato-
nin, also known chemically as N-acetyl-5-methoxytryp-
tamine, is a primary neurohormone secreted by pineal
gland. It is mostly found in retina and brain, and its
main function is thought to be the regulation of circa-
dian rhythm by translating photoperiodic information
from the eyes to the brain. There have been some stu-
dies suggesting that insulin level is regulated by circa-
dian clock. Furthermore, T2DM patients have exhibited
impaired melatonin secretion and circadian rhythm [10].
To date, several studies have shown the association
between MTNR1B and T2DM [6,11], but there has yet
to be a study which looked into the association between
MTNR1B and GDM. Since GDM shares many clinical
features with T2DM, there is a high possibility that
MTNR1B is associated with predisposition of GDM.
Therefore, we conducted an association study between
two polymorphisms of MTNR1B, which were previously
associated with T2DM, using 928 GDM patients and
990 controls. In addition, we also examined the possible
association between the two SNPs of MTNR1B and clin-
ical phenotypes related to GDM, such as insulin sensi-
tivity and beta-cell function.
Methods
Subjects
All 1,918 subjects included in this study were of Korean
ethnic origin and recruited from Cheil General Hospital
in Seoul, Korea, from 2003 to 2009. The clinical profiles
of the patients are summarized in Table 1. All pregnant
women who had not been previously diagnosed with
T2DM were screened for GDM using a universal two-
step GDM screening program at 24-28 week during
gestation (GDM patients mean gestational week = 26.03
± 2.69, NGT (Normal glucose tolerance) patients mean
gestational week = 26.12 ± 1.69, Table 1). The first step
was a 50-g glucose challenge test; if the result was posi-
tive (plasma glucose levels over 7.8 mmol/liter) after
1 hour, it was followed by conducting a 100-g, 3-hour
oral glucose tolerance test (OGTT) after overnight fast
according to criteria outlined by Carpenter and Coustan
[12]. The threshold glucose values were as follows: fast-
ing, at least 5.3 mmol/liter, 1 hour, at least 10.0 mmol/
liter, 2 hours, at least 8.6 mmol/liter, and 3 hours, at least
7.8 mmol/liter. Plasma glucose concentrations were mea-
sured by the glucose oxidase method using a YSI 2300
STAT (YSI; Yellow Springs, Ohio). Insulin concentra-
tions were measured using a human-specific radioimmu-
noassay kit (Linco Research, St. Charles, MO). If two or
more of the glucose values were met or exceeded the
above thresholds, GDM was diagnosed. A total of 928
GDM women were included in this study. 299 who were
negative for 50-gr glucose challenge test and 691 who
were pregnant and identified as normal glucose tolerant
after undergoing the 100 gr. Glucose challenge test. The
homeostasis model assessment (HOMA) index was used
to calculate beta-cell function (HOMA-B) and insulin
resistance (HOMA-IR) in various populations [13,14].
Our study conforms to the Helsinki declaration and also
to the Korean legislation. The institutional review board
of Cheil General Hospital approved the study, and all
subjects in the study provided informed consent.
SNP genotyping
Two polymorphisms of MTNR1B previously reported in a
T2DM association study were selected and were geno-
typed using a TaqMan [15] assay in the Korean popula-
tion. Genotyping quality control was performed in 10% of
the samples by duplicate checking (rate of concordance in
duplicates > 99%). The genotyping call success rates were
98.07% and 97.71% for rs1387153 and rs10830963, respec-
tively. The probes used were C_1932612_10 for rs1387153
and C_3256858_10 for rs10830963.
Statistical analyses
The allele distributions of polymorphisms among GDM
patients and normal subjects were evaluated by x
2 mod-
els calculating odds ratios (ORs), 95% confidence inter-
vals (CIs), and corresponding P values. We used SAS
version 9.1 (SAS Inc., Cary, NC) for the calculation.
Multiple regressions were used for association analyses
of GDM-related phenotypes adjusting for age and body
mass index (BMI) as covariates, also using SAS version
9.1. Linkage disequilibrium between the two SNPs were
calculated by the Haploview v4.1 software downloaded
from the Broad Institute http://www.broadinstitute.org/
mpg/haploview[16]. Statistical power of association was
calculated by using Power for Genetic Association soft-
ware [17]. For the calculation, disease prevalence of
GDM was estimated to be 3%, based on previous
researches [18], with risk allele frequencies of 0.503 and
0.521 for rs1387153 and rs10830963 respectively, and
odd ratios of 1.3 and 1.35, also for respective poly-
morphisms. With these parameters, it was calculated
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have over 90% statistical power with a type I error rate
of 0.05. In order to correct the data for multiple testing,
Bonferroni correction was applied. Also, we used
PHASE software for haplotype inference [19], and
inferred haplotypes were analyzed using SAS version 9.1
for the logistic analyses.
Also, we used PHASE software to estimate individual
haplotypes and their frequencies, which uses a Bayesian
approach. Individuals with phase probabilities less than
97% were excluded in analysis. To analyze the associations
of haplotypes, we used Haplo.stats http://mayoresearch.
mayo.edu/schaid_lab/software.cfm, which provides several
haplotype-specific tests for association, as well as adjust-
ment for non-genetic covariates and computation of simu-
lation P-values. We also conducted conditional analyses
with PLINK software http://pngu.mgh.harvard.edu/~pur-
cell/plink/.
Results
Nine hundred and twenty eight GDM patients were
recruited for the present study, and we also recruited 990
pregnant women with normal glucose tolerance as con-
trols. The clinical profiles of the subjects are summarized
in Table 1, with characteristics related with T2DM such
as the area under glucose curve (AUC-G), fasting plasma
insulin (FPI), and fasting plasma glucose (FPG). We also
obtained homeostatic model assessment data for both
groups in beta-cell function and insulin resistance
(HOMA-B and HOMA-IR, respectively). Most of the
phenotypes investigated for the subjects showed signifi-
cant difference between the GDM patients group and the
control group, (Table 1, P value < 0.0001 for all pheno-
types except mean gestational week), which was to be
expected because the phenotypes that showed the signifi-
cant differences were associated with the diabetic condi-
tion. GDM patients were older, possessed higher BMI
than the NGT women and clearly exhibited the clinical
characteristics of T2DM, as shown in Table 1; in compar-
ison to NGT women, GDM patients exhibited higher
blood glucose levels and lower beta-cell function when
insulin resistance was increased.
We first performed association analyses of the two
genetic polymorphisms in GDM and non-GDM subjects
to determine whether these polymorphisms were asso-
ciated with a higher risk of developing GDM, which
were previously found to be associated with T2DM
(rs1387153 and rs10830963 on MTNR1B),w i t ht h er i s k
of GDM (Table 2). The risk allele frequencies of both
SNPS are also shown in Table 2. As a result, both SNPs
showed significant associations with GDM in co-domi-
nant, dominant, and recessive models. Co-dominant
model exhibited lowest P value (0.00008, Pcor. = 0.0006,
OR (95% CI) = 1.30 (1.06 - 1.66) and 0.00001, Pcor.=
0.00008, OR = 1.35 (1.18 - 1.54) for rs1387153 and
rs10830963, respectively), and recessive model showed
highest P value (0.002, OR = 1.42 (1.14 - 1.78) and
0.0001, OR = 1.54 (1.23 - 1.92) respectively for
rs1387153 and rs10830963, respectively), while dominant
model P value was in between the two (0.0007, OR (95%
CI) = 1.44 (1.17 - 1.78) and 0.0006, OR = 1.46 (1.18 -
1.81) for rs1387153 and rs10830963, respectively). The
risk allele for rs1387153 was T, and for rs10830963,i t
was G. P-value for Hardy-Weinberg equilibrium of sub-
jects and controls were over 0.05 for both SNPs, indicat-
ing that the sample population is in Hardy-Weinberg
equilibrium (data not shown). Also, there was a signifi-
cantly high value of linkage disequilibrium (LD) between
the two SNPs (|D’| = 0.89). The association results of
haplotypes with the 2 SNPs are shown in Table 3 and 4.
We have also performed regression analysis with var-
ious diabetes-related phenotypes, including body mass
index (BMI, analyzed controlling for age and the num-
ber of parities as covariate), AUC-G, HOMA-B,
HOMA-IR, FPI and FPG, with age, BMI, and numbers
of parities as covariates (Table 5). From the analyses,
both SNPs showed significant associations for AUC-G,
HOMA-B, and FPG with phenotypes among all subjects
(Table 5). The rare alleles of the 2 SNPs were associated
with bigger AUC-G, lower HOMA-B, and higher FPG,
Table 1 Clinical profiles of subjects
Profiles GDM Controls P value
Number of subjects 928 990
Age(yr) 33.17 (22-52) 32.24 (23-44) <0.0001
Mean gestation week (wk) 26.03 ± 2.69 26.12 ± 1.69 0.37
BMI(kg/m2) 23.32 ± 4.01 21.40 ± 2.93 <0.0001
AUC-G (Area under glucose curve) 482.46 ± 57.04 358.72 ± 39.99 <0.0001
HOMA-B (Homeostatic model assessment, b-cell function) 208.06 ± 112.75 268.30 ± 179.88 <0.0001
HOMA-IR (Homeostatic model assessment, insulin resistance) 3.07 ± 1.76 2.14 ± 1.02 <0.0001
Fasting plasma insulin (pmol/liter) 13.51 ± 6.62 10.82 ± 4.72 <0.0001
Fasting plasma glucose (pmol/liter) 89.95 ± 13.72 79.31 ± 6.11 <0.0001
Data are presented as means ± standard deviation except age. Data are presented as SD.
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Page 3 of 8Table 2 Allele and genotype distributions of MTNR1B polymorphisms in GDM and control subjects
Loci Genotype RAF N (%) Referent Co-dominant Dominant Recessive
GDM Controls GDM Controls OR(95%CI) Pcor. OR(95%CI) Pcor. OR(95%CI) Pcor. OR(95%CI) Pcor.
CC 235(25.9%) 313(32.2%) 1
CT 433(47.6%) 455(46.8%) 1.33 0.1 1.3 0.0008 1.44 0.008 1.42 0.03
rs1387153 0.503 0.444 (1.06-1.66) (1.14-1.49) (1.17-1.78) (1.14-1.78)
TT 241(26.5%) 204(21.0%) 1.29 0.001
(1.13-1.47)
CC 217(23.9%) 294(30.4%) 1
CG 435(47.9%) 469(48.6%) 1.31 0.2 1.35 0.0001 1.46 0.006 1.54 0.001
rs10830963 0.521 0.453 (1.04-1.65) (1.18-1.54) (1.18-1.81) (1.23-1.92)
GG 256(28.2%) 203(21.0%) 1.34 0.0001
(1.18-1.53)
P values were corrected for multiple testing by multiplying the number of tests (10 tests, 2 SNPs × 5 tests (2 referent, co-dominant, dominant and recessive models)) (Bonferroni correction). RAF, risk allele frequency.
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8and these alleles were the risk alleles for GDM (T for
rs1387153 and G for rs10830963). To see if a certain
SNP was functional, we have performed conditional ana-
lyses for GDM and other phenotypes. The results are
listed in Table 6. From the results, rs10830963 retained
its signal, while the significance of rs1387153 was disap-
peared, which suggest that rs1387153 might have shown
its signal because of its LD with rs10830963, although
not clear in GDM-related phenotype analyses.
Discussion
In previous studies on the rs1387153 and rs10830963,
researchers found strong associations between the two
SNPs of MTNR1B and T2DM, and also with FPG levels,
which is an important phenotype for diabetes. A study
in European population, which included French and
Danish among other nations, showed that rs1387153
was significantly associated with FPG level (P =1 . 3×
10
-7, adjusted genome-wide P = 0.04) and T2DM (OR
(95% CI) = 1.15(1.08-1.22), P =6 . 3×1 0
-5). Another
study in European population found significant associa-
tions of rs10830963 with FPG (P =3 . 2×1 0
-50)a n d
T2DM (OR (95% CI) = 1.09(1.05-1.12), P =3 . 3×1 0
-7).
The Two SNPs were closely related with each other, as
evidenced by the linkage disequilibrium test (|D’|=
0.89) in our study. Their haplotype analyses results
Table 4 MTNR1B haplotypes’ genotype distribution, means and standard deviations of various phenotypes for GDM
Phenotype Loci C/C C/R R/R
BMI ht1 518(22.34 ± 3.70) 904(22.34 ± 3.62) 454(22.35 ± 3.59)
ht2 584(22.39 ± 3.64) 896(22.35 ± 3.63) 396(22.28 ± 3.62)
ht3 1719(22.31 ± 3.58) 152(22.72 ± 4.04) 5(23.54 ± 6.94)
ht4 1788(22.36 ± 3.65) 86(22.16 ± 3.21) 2(19.80 ± 1.41)
AUC_G ht1 449(438.33 ± 74.35) 757(429.75 ± 79.48) 375(420.39 ± 84.28)
ht2 480(420.98 ± 83.23) 753(430.50 ± 78.91) 348(441.20 ± 73.83)
ht3 1446(430.46 ± 80.09) 130(425.51 ± 72.41) 5(405.10 ± 75.33)
ht4 1516(429.95 ± 79.07) 64(431.35 ± 88.89) 1(361.50)
HOMA_B ht1 509(225.47 ± 126.01) 898(240.16 ± 144.09) 448(254.96 ± 200.10)
ht2 577(251.20 ± 186.38) 889(240.64 ± 143.02) 389(220.51 ± 128.44)
ht3 1700(239.45 ± 157.09) 150(242.64 ± 138.61) 5(239.14 ± 23.78)
ht4 1768(239.99 ± 157.73) 85(232.89 ± 98.82) 2(280.10 ± 66.75)
HOMA_IR ht1 512(2.66 ± 1.60) 898(2.58 ± 1.45) 450(2.54 ± 1.50)
ht2 579(2.54 ± 1.61) 889(2.59 ± 1.34) 392(2.68 ± 1.68)
ht3 1705(2.59 ± 1.46) 150(2.65 ± 1.95) 5(2.58 ± 1.28)
ht4 1773(2.60 ± 1.52) 85(2.42 ± 1.16) 2(2.00 ± 0.24)
FPI ht1 512(12.34 ± 6.48) 898(12.09 ± 5.64) 450(12.00 ± 5.71)
ht2 579(11.98 ± 6.12) 889(12.15 ± 5.31) 392(12.35 ± 6.78)
ht3 1705(12.11 ± 5.74) 150(12.45 ± 7.54) 5(12.36 ± 4.49)
ht4 1773(12.17 ± 5.96) 85(11.51 ± 4.61) 2(10.50 ± 0.71)
FPG ht1 449(86.46 ± 12.66) 757(85.32 ± 11.89) 375(84.49 ± 13.30)
ht2 480(84.49 ± 12.83) 753(85.40 ± 11.82) 348(86.86 ± 13.23)
ht3 1446(85.53 ± 12.66) 130(84.65 ± 10.31) 5(82.20 ± 9.36)
ht4 1516(85.44 ± 12.50) 64(85.64 ± 11.87) 1(80.00)
C/C, C/R, and R/R indicate major homozygote, heterozygote, and minor homozygote, respectively.
FPI, fasting plasma insulin; FPG, fasting plasma glucose.
Table 3 Haplotype association analyses with GDM and GDM-related phenotypes
Haplotype Frequency Phenotype
GDM(case/control) BMI AUC_G* HOMA_B* HOMA_IR* FPI* FPG
ht1 (C-C) 0.452 0.0001 0.93 0.0004 0.002 0.19 0.35 0.01
ht2 (T-G) 0.486 0.000001 0.8 0.00007 0.002 0.08 0.23 0.002
ht3 (C-G) 0.045 0.25 0.15 0.25 0.8 0.66 0.94 0.17
ht4 (T-C) 0.018 0.008 0.42 0.94 0.82 0.37 0.44 0.77
Haplotypes were estimated by using PHASE software (Stephens et al.). The association analyses and regression analyses for haplotypes were done by using
Haplo. stats (Schaid et al.). P values for phenotypes were calculated from multiple linear regression analyses controlling for age, BMI, and number of parities as
covariates except BMI phenotypes, which were adjusted for age and number of parities as covariates only. P values for phenotypes shown are co-dominant
model. * P values for AUC_G, HOMA_B, HOMA_IR, and FPI were calculated after normalizing their data by applying logarithms.
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tagged by rs10830963 and rs1387153, respectively
(>92%). Therefore, ht1/ht2 showed similar associations
with each SNP, respectively.
Here, we performed the association studies in Korean
pregnant women and we found significant associations
between the SNPs and GDM, with enough samples for
high statistical power. It is well known that T2DM and
GDM are closely related diseases, since they exhibit
similar characteristics such as glucose intolerance. How-
ever, there had yet to be a study that looked into the
association between the polymorphisms of MTNR1B
and GDM, and our study confirmed the relations
between the two. Also, we carried out regression ana-
lyses between the polymorphisms of MTNR1B and var-
ious phenotypes including FPG. Although both SNPs
showed associations with GDM and FPG, our results
suggested that the two genetic variants of MTNR1B
were stronger risk factors for GDM in Korean popula-
tion compared to the previous results for T2DM in Eur-
opean population (OR (95% CI) = 1.44 (1.17-1.78) for
rs1387153 in dominant inheritance model and 1.46 (1.18
- 1.81) for rs10830963 in the present study and OR =
1.15 (1.08-1.22) for rs1387153 and OR = 1.09 (1.05-1.12)
for rs10830963 in the two previous studies). We suspect
that the genetic differences between GDM and T2DM
and the population difference between Europeans and
Asians could have contributed to this result. Previously,
there have been a few cases where a gene associated
with T2DM was not associated with GDM at all [20], or
showed different effect sizes [21,22], and our results sug-
gest that MTNR1B affects T2DM and GDM in varying
degrees as well.
Moreover, our results suggest that the two poly-
morphisms investigated are associated with beta-cell
function (Table 5). Association between beta-cell func-
tion and MTNR1B was previously reported [18,23],
which shows that we were able to replicate the result in
Korean population, strengthening the notion that
MTNR1B polymorphisms are related with impaired
Table 6 Conditional association analyses of MTNR1B
genetic variants
Phenotype Loci P Conditioned P value by
rs1387153 rs10830963
GDM rs1387153 0.00008 - 0.007
rs10830963 0.00001 0.22 -
BMI rs1387153 0.66 - 0.59
rs10830963 0.77 0.51 -
AUC_G* rs1387153 0.00002 - 0.34
rs10830963 0.00006 0.11 -
HOMA_B* rs1387153 0.0004 - 0.25
rs10830963 0.0007 0.07 -
HOMA_IR* rs1387153 0.15 - 0.28
rs10830963 0.14 0.12 -
FPI* rs1387153 0.58 - 0.89
rs10830963 0.49 0.49 -
FPG rs1387153 0.0004 - 0.36
rs10830963 0.001 0.85 -
Conditional P values were estimated and permutated using the software
PLINK (Purcell et al.). * P values for AUC_G, HOMA_B, HOMA_IR, and FPI were
calculated after normalizing their data by applying logarithms.
Table 5 Multiple regression analyses of MTNR1B polymorphisms with diabetes-related phenotypes among all subjects
Phenotype Loci C/C C/R R/R Pacor. Pbcor. Pccor.
BMI rs1387153 548(22.38 ± 3.65) 888(22.37 ± 3.65) 445(22.24 ± 3.56) 1 1 1
rs10830963 511(22.34 ± 3.60) 904(22.33 ± 3.58) 459(22.37 ± 3.75) 1 1 1
AUC_G* rs1387153 454(419.91 ± 81.85) 743(431.31 ± 79.96) 386(439.26 ± 74.28) 0.0007 0.004 0.03
rs10830963 419(421.23 ± 85.41) 763(429.09 ± 78.39) 403(439.14 ± 74.58) 0.002 0.04 0.03
HOMA_B* rs1387153 541(252.38 ± 190.86) 882(239.90 ± 143.11) 437(222.90 ± 125.81) 0.01 0.29 0.07
rs10830963 505(251.36 ± 191.00) 897(240.78 ± 143.84) 451(223.74 ± 128.37) 0.03 0.72 0.04
HOMA_IR* rs1387153 543(2.53 ± 1.63) 882(2.59 ± 1.35) 440(2.64 ± 1.62) 1 1 1
rs10830963 507(2.53 ± 1.47) 897(2.57 ± 1.43) 454(2.69 ± 1.65) 1 1 1
FPI* rs1387153 543(11.98 ± 6.21) 882(12.15 ± 5.34) 440(12.26 ± 6.56) 1 1 1
rs10830963 507(11.91 ± 5.59) 897(12.07 ± 5.61) 454(12.44 ± 6.64) 1 1 1
FPG rs1387153 454(84.30 ± 12.71) 743(85.55 ± 12.01) 386(86.58 ± 12.94) 0.01 0.07 0.22
rs10830963 419(84.63 ± 13.24) 763(85.13 ± 11.62) 403(86.71 ± 12.99) 0.04 0.72 0.07
P value was calculated from multiple linear regression analyses controlling for age, BMI, and number of parities as covariates except BMI phenotypes, which was
adjusted for age and number of parities as covariates only. Pa, Pb, and Pc designate P values for co-dominant, dominant, and recessive models, respectively. P
values were corrected for multiple testing by multiplying the number of tests (36 tests, 2 SNPs × 3 models × 6 phenotypes) (Bonferroni correction). C/C, C/R, and
R/R indicate major homozygote, heterozygote, and minor homozygote, respectively. * P values for AUC_G, HOMA_B, HOMA_IR, and FPI were calculated after
normalizing their data by applying logarithms (Data shown are raw values). FPI, fasting plasma insulin; FPG, fasting plasma glucose.
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have studied the association between the gene variants
of MTNR1B and glucose tolerances. rs10830963 was
found to be associated with FPG and decreased beta-cell
function in a group of obese children, which is consis-
tent with our finding [24]. Three independent studies of
the MTNR1B genetic variants in Han Chinese subjects
also found significant associations for increased FPG,
impaired beta-cell function, glycated hemoglobin, and
T2DM [18,25,26]. Furthermore, a study with European
populations also found significant associations between
variations of MTNR1B with BMI and FPG, but not with
maturity-onset diabetes of the young (MODY) or T2DM
[27]. Although some of their results do not agree with
each other in the association with T2DM, these findings
firmly back up the association between the SNPs in our
study and FPG or impaired beta-cell function. On the
other hand, we could not find any significant associa-
tions between insulin resistance (HOMA-IR) and the
two genetic variants. Since our results are backed with
high statistical power, this leads us to conclude that two
genetic variants of MTNR1B may be associated with the
disease by affecting glucose metabolism through
impaired insulin secretion, as previously suggested by
other studies with KCNQ1 genetic variants [8,18,28].
In addition, further conditional analyses results sug-
gested that rs10830963 might be more likely functional
in case/control analysis, although not clear in GDM-
related phenotype analyses.
Although our results showed the significant associa-
tions with GDM and several diabetic characteristics,
there are a couple of limitations. First, our study only
concentrated on pregnant women among Korean popu-
lation, so we cannot conclude that the MTNR1B gene
variants are associated with FPG or impaired beta-cell
function in all Korean population. Also, even though
our study strongly suggests that the SNPs may also be
associated with T2DM in Korean population, this is not
confirmed yet. Any further studies on these two genetic
variants in Korean population should concentrate on
these parts.
Conclusions
The present study showed that two MTNR1B poly-
morphisms were associated with increased risk for
GDM in Korean female population. Two polymorphisms
rs1387153 and rs10830963 also showed significant asso-
ciations with FPG and beta-cell function, but not with
insulin resistance. Further conditional analyses results
suggested that rs10830963 m i g h tb em o r el i k e l yf u n c -
tional in case/control analysis, although not clear in
GDM-related phenotype analyses. The effective sizes
found between the two polymorphisms and FPG was
stronger compared to previous studies, which is possibly
due to the genetic difference between European and
Korean populations, or the difference between GDM
and T2DM. Based on the current results, we suspect
that these two polymorphisms will have significant asso-
ciations with increased risk of GDM in other popula-
tions as well. Also, our discovery would be helpful for
understanding of genetic etiology of GDM as well.
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